Literature DB >> 12419930

Serum hepatocyte growth factor predicts ventricular remodeling following myocardial infarction.

Takeshi Soeki1, Yoshiyuki Tamura, Hisanori Shinohara, Koichi Sakabe, Yukiko Onose, Nobuo Fukuda.   

Abstract

Hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) stimulate endothelial cell proliferation and induce angiogenesis, but the timing and significance of their release in patients with acute myocardial infarction (AMI) are unknown in relation to future left ventricular remodeling. Venous blood samples were obtained at admission and up to 3 weeks later in 40 patients with AMI and in 40 age- and sex-matched control subjects. Blood samples were also taken from the coronary sinus (CS) in 20 patients on day 7 following AMI. Left ventricular end-diastolic volume in the subacute (1 week) and chronic (3 months) phases was assessed by left ventriculography to identify the remodeling group (n=15), which was defined as an increase in left ventricular end-diastolic volume index > or =5 ml/m(2) relative to the baseline value. Serum HGF and VEGF concentrations were higher in newly admitted patients with AMI than in the controls (HGF, 0.33 +/-0.09 vs 0.24+/-0.08 ng/ml, p<0.01; VEGF, 92.2+/-43.1 vs 67.2+/-29.8 pg/ml, p<0.01), peaking on day 7 (HGF, 0.41+/-0.12; VEGF, 161.7+/-76.9), and gradually decreasing between days 14 and 21. The HGF concentration in the CS did not differ from the concentration in the periphery, but the VEGF concentration was significantly more abundant in the CS than in the peripheral sample on day 7 (p<0.05). The serum HGF concentration on day 7 was higher in the remodeling group than in the nonremodeling group (0.47 +/-0.13 vs 0.36+/-0.09 ng/ml, p<0.01), but there was no difference between the groups on admission, day 14 and day 21. The serum VEGF concentration did not differ between the remodeling and nonremodeling groups at any time. Thus, the serum HGF concentration on day 7 after AMI is mostly from noncardiac sources and predicts left ventricular remodeling.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12419930     DOI: 10.1253/circj.66.1003

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  5 in total

Review 1.  Diagnosis of hepatocellular carcinoma.

Authors:  Asmaa I Gomaa; Shahid A Khan; Edward L S Leen; Imam Waked; Simon D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

2.  Correlation between vascular endothelial growth factor and long-term prognosis in patients with acute myocardial infarction.

Authors:  Jiamin Niu; Xia Han; Huaxin Qi; Jie Yin; Zhiqiang Zhang; Zengtang Zhang
Journal:  Exp Ther Med       Date:  2016-04-21       Impact factor: 2.447

3.  Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma.

Authors:  S Karabulut; F Tas; F Akyüz; A C Ormeci; M Serilmez; H O Soydinç; S Vatansever; V Yasasever
Journal:  Tumour Biol       Date:  2013-10-20

4.  Association between the ratio of anti-angiogenic isoform of VEGF-A to total VEGF-A and adverse clinical outcomes in patients after acute myocardial infarction.

Authors:  Kazuhiro Harada; Ryosuke Kikuchi; Hideki Ishii; Yohei Shibata; Susumu Suzuki; Akihito Tanaka; Atsuo Suzuki; Kenshi Hirayama; Toyoaki Murohara
Journal:  Int J Cardiol Heart Vasc       Date:  2018-03-22

5.  Serum vascular endothelial growth factor level is elevated in patients with impaired glucose tolerance and type 2 diabetes mellitus.

Authors:  Xiaomeng Sun; Heng Zhang; Jia Liu; Guang Wang
Journal:  J Int Med Res       Date:  2019-09-23       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.